Quotient Clinical acquires its second GMP manufacturing plant and builds new labs
Expanding formulation development capabilities and doubling capacity
UK-based translational pharmaceutics company Quotient Clinical is significantly expanding its pharmaceutical sciences capabilities and doubling capacity with the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories in Nottingham.
The company says the new laboratories, based within its existing Nottingham facility, were commissioned in response to increasing demand for its formulation development services, and have a footprint of approximately 8,000ft2 (740m2).
The GMP manufacturing facility, comprising eight multipurpose suites, is located in the MediCity innovation hub in Nottingham, and has a footprint of 3,000ft2 (280m2). It will allow the company to manufacture drug products on a large scale, with all the necessary containment controls to enable safe handling of high potency molecules. The facility is scheduled to become operational later this year following an MHRA inspection.
Quotient Clinical's CEO Mark Egerton said: 'This expansion is in direct response to the increasing demand for our translational pharmaceutics services. Our approach of integrating formulation development, real-time GMP manufacturing and clinical testing is proving an attractive option to reduce development timelines and associated costs.'
